| PRECLINICAL | evidence | Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study. | Semaglutide | — | 2026-06-02 |
| PRECLINICAL | evidence | Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. | Semaglutide | — | 2026-06-02 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Real-world outcomes of hybrid obesity care using digital coaching and GLP-1 therapy in a multi-ethnic Asian setting. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. | Semaglutide | Sleep quality | 2026-06-01 |
| PRECLINICAL | evidence | Glycemic and cardiometabolic effects of rare sugars allulose and tagatose: a systematic review and meta-analysis of controlled human intervention trials. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis. | Ozempic | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Cardiometabolic Profiles and Treatment Trajectories of GLP-1 Receptor Agonist Users With Obstructive Sleep Apnea: Real-World Evidence From a Large Private Healthcare Cohort in Poland. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Body image in the age of GLP-1s: Emerging questions for research and practice. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Remission of erythromelalgia after semaglutide initiation: A case report. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Semaglutide Reverses Ectopic Lipid Accumulation, Impaired Myocardial Perfusion Reserve, and Diastolic Dysfunction in a Mouse Model of Cardiometabolic Heart Disease. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Semaglutide-associated Twiddler syndrome. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25. | Semaglutide | Cognition & memory | 2026-06-01 |
| PRECLINICAL | evidence | The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review. | Semaglutide | Cognition & memory | 2026-06-01 |
| PRECLINICAL | evidence | Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large. | Ozempic | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | [Advances in Anti-Dementia Therapies in Older Adults]. | Semaglutide | Cognition & memory | 2026-06-01 |
| PRECLINICAL | evidence | Comment on Shah and Ayala. Interpreting Stage-Dependent Changes in Semaglutide Response: From Patterns to Mechanisms. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Response to Comment on Shah and Ayala. Interpreting Stage-Dependent Changes in Semaglutide Response: From Patterns to Mechanisms. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | ICER report demonstrates both the value and challenges in financing of weight loss medications. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Photodistributed exfoliative dermatitis associated with semaglutide: Expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. | Semaglutide | — | 2026-06-01 |